Artia Global Partners’s Immunovant IMVT Stock Holding History

Artia Global Partners’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-21,397	Closed	-$691K	–	51
2024 Q1	$691K	Hold	21,397	–	–	0.14%	43
2023 Q4	$901K	Buy	+21,397	New	+$787K	0.26%	25

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Artia Global Partners's IMVT Position: Q2 2024 in Review

Artia Global Partners sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 21,397 shares — an estimated $691K sold.

Artia Global Partners first reported a position in IMVT in Q4 2023 and held it in 2 quarters. The position peaked at $901K in Q4 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

Artia Global Partners reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
Artia Global Partners sold 21,397 Immunovant shares in Q2 2024, an estimated $691K.
Artia Global Partners first reported a position in Immunovant in Q4 2023 and held it in 2 quarters.
Artia Global Partners's Immunovant position peaked at $901K in Q4 2023.
197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Artia Global Partners's 13F filing for Q2 2024, filed 14 Aug 2024.